Company and Industry Overview * **Company**: Amgen Inc. (NASDAQ: AMGN) * **Industry**: Biopharmaceuticals * **Focus**: Developing innovative medicines for unmet medical needs in general medicine, oncology, inflammation, and rare diseases. Key Points Business Performance * **General Medicine**: Repatha and EVENITY continue to grow strongly, with Repatha up 25% in Q2 2024 and EVENITY up 40%. * **Oncology**: Oncology portfolio up 12% on the quarter, driven by strong performance across multiple medicines. * **Inflammation**: TEZSPIRE grew 75% in Q2 2024, with potential to be a game-changing medicine. * **Rare Diseases**: TEPEZZA, KRYSTEXXA, and UPLIZNA are performing well, with UPLIZNA showing spectacular data in IgG4-related disease. * **Pipeline**: Strong pipeline with visible molecules in each area, including bispecifics, novel biologics, and next-generation assets. Strategy and Growth * **Innovation**: Focus on innovation and addressing unmet medical needs. * **International Growth**: Well-established globally, with strong growth in Asia and other international markets. * **Pipeline**: Exciting pipeline with multiple late-stage programs and next-generation assets. * **Biosimilars**: Developing biosimilars to augment existing products and expand market access. Policy and Regulatory * **Inflation Reduction Act (IRA)**: Concerns about the impact of IRA on innovation and investment in the industry. * **Policy Engagement**: Active engagement in Washington D.C. to ensure understanding of the biopharmaceutical industry and the impact of policies like IRA. Pipeline Details * **MariTide**: Next-generation obesity asset with a different mechanism of action and dosing advantage compared to existing treatments. * **Rocatinlimab**: Novel OX40 antibody for atopic dermatitis, prurigo nodularis, and respiratory diseases. * **Olpasiran**: Novel Lp(a) lowering therapy for patients at high risk of cardiovascular disease. * **AI**: Investing in AI to accelerate drug discovery and development. Other Important Points * **Horizon Integration**: Integration of Horizon Therapeutics is progressing well, with a strong fit between teams and exciting potential for future growth. * **Puerto Rico Tax Litigation**: High confidence in a favorable outcome in the tax court later in the year.

THOUSAND OAKS, Calif., Aug. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday, Sept. 5, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, i ...

THOUSAND OAKS, Calif., Aug. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 9:15 a.m. ET on Wednesday, Sept. 4, 2024. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments ...

Amgen HQ in Thousand Oaks, CA JHVEPhoto Earlier this month, Wells Fargo cut its rating on Amgen (NASDAQ:AMGN), stating that success of its GLP-1 candidate MariTide was already priced into the shares. However, trading at 16.6x next year's earnings, the stock seems fairly valued despite 27% price appreciation over the past year. Existing product lines provide a strong foundation for the Amgen's valuation, while a successful conclusion to MariTide's crucial phase II study may provide a bullish catalyst later t ...

PeopleImages Since the publication of my last article, "Amgen: You Haven't Seen Anything Yet," Amgen's (NASDAQ:AMGN) share price has risen by more than 20%, thanks in part to increased speculative interest ahead of upcoming clinical results for MariTide in treating patients suffering from obesity, strong sales of its oncology and osteoporosis franchises, as well as medicines acquired in the Horizon Therapeutics deal. What will be presented in this article? I will discuss in detail several topics that ar ...

First and Only Pill for Children and Adolescents Ages 6-17 with Moderate to Severe Plaque PsoriasisTHOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or sy ...

Amgen has many growth opportunities ahead, and it also pays a fairly high dividend.If you're looking for a top healthcare company to invest in, you may want to consider looking at one that has multiple fast-growing products in its portfolio. By seeking out diversified growth stocks, you can minimize your risk and reduce significant volatility. If a company has a diverse product mix, it has many ways to grow its operations without being too dependent on a single asset.Amgen (AMGN -0.53%) is coming off a stro ...

Urilux/E+ via Getty Images Investment Overview Amgen Inc. (NASDAQ:AMGN), the Thousand Oaks, California based Pharma giant, reported its Q2 2024 earnings this Tuesday, August 6th. The last time I covered Amgen for Seeking Alpha was in May this year, following Q1 earnings. I gave Amgen stock a “buy” rating, when shares traded at $311, and they subsequently reached a high of $335 — up ~8%, before dipping after Q2 results were announced. First, let's consider the headline figures. Revenues grew by an impres ...

Key TakeawaysAmgen shares fell 5% Wednesday after the drug developer lowered its full-year earnings guidance.Second-quarter revenue jumped 20% year-over-year to $8.4 billion, slightly above expectations, driven by Amgen's October acquisition of Horizon Therapeutics.However, earnings dropped from the year-ago period and missed estimates as costs rose. Amgen (AMGN) shares tumbled 5% Wednesday after the drug developer lowered its full-year earnings guidance. The company said it now expects full-year diluted ea ...

On Tuesday, Amgen Inc. AMGN reported mixed second-quarter results.BMO Capital Markets writes, “A commercially in-line quarter for Amgen underscores the importance of upcoming clinical readouts in obesity and inflammatory disease.” The analyst keeps the Outperform rating with a price target of $362.The analyst notes that while the company’s base business underperformed (Enbrel -6% and Repatha -1% compared to consensus), its growth portfolio had some strength. However, they anticipate greater momentum from Ho ...